Singapore and Princeton, NJ – March 27, 2025 – Shanton Pharma, a clinical-stage biotech company developing a novel treatment for gout, today announced topline data of a Phase 2b study in refractory gout patients with its investigational drug SAP-001 that uses a First-in-Class Mechanism of Action targeting a distinct kidney transporter.

SAP-001 is Shanton’s lead investigational compound with Best-in-Class potential in uncontrolled gout

The Shanton Pharma Phase 2 study evaluating its investigational product SAP-001, an oral, small molecule, achieved its primary endpoint. In the trial, SAP-001 significantly reduce uric acid . SAP-001 was well tolerated.

– Established China Biotechnology Company with Global Headquarters in the United States – Proceeds will advance clinical development of SAP-001 clinical trials for hyperuricemia and gout Based in Shanghai, Shanton Pharma is a private clinical-stage biotechnology company dedicated to the research, development and commercialization of innovative medicines in areas of unmet medical need, closed a $31.2 million Series A+ financing in December of 2020. The proceeds will be used to accelerate the p